Plaa Protein (Phospholipase A2 Activating Protein) plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Plaa Protein (Phospholipase A2 Activating Protein) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
PLAA
| Protein Name | PLAA |
| Gene | PLAA |
| UniProt ID | Q9NSC7 |
| Molecular Weight | ~90 kDa |
| Subcellular Localization | Cytoplasm, nucleus |
| Protein Family | PLAA family |
| Associated Diseases | Neurodegeneration, Alzheimer's Disease, Inflammatory Diseases |
PLAA is a multi-domain protein containing:
The PFU domain is structurally unique and binds ubiquitin through a hydrophobic pocket, allowing PLAA to function as a ubiquitin receptor in various cellular processes. PLAA forms homodimers and can also associate with other proteins to form larger complexes.
PLAA has multiple cellular functions:
cPLA2 activation: PLAA acts as a co-activator for cytosolic phospholipase A2 (cPLA2), enhancing its activity and promoting arachidonic acid release. This is the rate-limiting step in eicosanoid (prostaglandins, leukotrienes) synthesis.
Ubiquitin-proteasome system: Through its PFU domain, PLAA binds ubiquitinated substrates and delivers them to the proteasome for degradation. This function is crucial for protein quality control.
Autophagy: PLAA is involved in selective autophagy through its ubiquitin-binding function, helping to clear damaged organelles and protein aggregates.
ER-associated degradation (ERAD): PLAA participates in retrotranslocation of misfolded proteins from the ER for cytosolic degradation.
PLAA dysfunction contributes to neurodegeneration through several mechanisms:
Alzheimer's Disease:
Protein aggregation:
Neuroinflammation:
Therapeutic strategies targeting PLAA:
cPLA2 inhibitors: Pyrrolidine derivatives and natural compounds inhibiting cPLA2 are being developed to reduce neuroinflammation.
Proteostasis modulators: Enhancing proteasome activity to compensate for PLAA-mediated degradation defects.
Anti-inflammatory approaches: Targeting downstream inflammatory pathways activated by eicosanoids.
Autophagy enhancers: Promoting clearance of protein aggregates through autophagy.
Plaa Protein (Phospholipase A2 Activating Protein) plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Plaa Protein (Phospholipase A2 Activating Protein) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.